中国买的到非布司他吗？

It is a selective xanthine oxidase inhibitor that has a clear uric acid-lowering effect. It can reduce the level of uric acid in the body by inhibiting the production of uric acid.

Compared with allopurinol, it is more effective in treating uric acid and has relatively fewer side effects.

Febuxostat is also a selective xanthine oxidase inhibitor. Its uric acid-lowering effect is also very good, and its side effects are relatively low. Compared with allopurinol, it does not have the side effects of fatal exfoliative dermatitis. Can febuxostat be purchased in China?

Purchase channels for Buxostat: It is understood that Febuxostat has been on the market in China since 2013. Patients can purchase it at major hospitals or pharmacies in China with a prescription issued by a doctor!

When it comes to buying medicine, the first thing that comes to mind is the price issue. The price of febuxostat on the domestic market is relatively expensive and is not suitable for patients to take it for a long time. What I need to tell you here is that the febuxostat produced by Zydus Pharmaceuticals in India has the same efficacy as the original drug, but the price is indeed much lower. The specification is 80mg*30 tablets/box. Its price is about 200$. Due to the floating exchange rate, the price is different. Please consult the medical companion for the specific price!

If you want to buy the Indian version of Febuxostat and it is inconvenient to go abroad, the most reliable way is to buy it through a regular overseas medical service institution in China, which will sign a guarantee contract for you. The medicine and money will not be handled, and will be mailed to the patient by direct mail, ensuring 100% authenticity!

How to administer febuxostat:

40 mg or 80 mg once daily is recommended. The recommended starting dose of febuxostat is 40 mg once daily. For patients who do not achieve serum uric acid (sUA) less than 6 mg/dL 2 weeks after taking 40 mg, febuxostat 80 mg is recommended.

Recommended related hot articles: /newsDetail/74732.html